Ocular Therapeutix (OCUL) announced that more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI, and the trial is expected to close randomization this week. This is the first registrational clinical trial of AXPAXLI in wet age-related macular degeneration, which remains on track to report topline data in the fourth quarter of 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL: